The Resting-state EEG Gamma Oscillations in Alzheimer's Disease

Görsev Yener, MD, PhD

Status: Completed

Conditions: Alzheimer Disease, Early Onset

Treatments: Diagnostic Test: CSF

Study type: Observational

Funder types: Other

Identifiers

NCT05989087

DokuzEU EEG

Details and patient eligibility

About

The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Full description

This cross-sectional study included 24 drug-naive CSF-proven EOAD patients and age-, sex, and education-matched healthy controls. All participants underwent a detailed neuropsychological evaluation, resting-state electroencephalography (EEG) recording, and Magnetic Resonance Imaging (MRI). Gamma power and coherence were measured in total gamma (30-48 Hz), gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz) frequency bands. Gray matter volumes were extracted for 54 regions of interest (ROIs) and compared between groups. Discriminant analysis was performed to determine the classification accuracy of gamma activity for EOAD. Finally, correlations between CSF, neuropsychological tests, EEG, and MRI measures were explored.

Enrollment: 51 patients

Sex: All

Ages: Under 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• For all participants: Age < 65
• For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria.
• For healthy controls: Mini-Mental State Examination (MMSE) >25 Instrumental Activities of Daily Living Scale (IADL) = 8

Exclusion criteria

• For EOAD patients: MMSE > 24 Geriatric depression scale (GDS) > 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities.
• For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS > 14
• For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)

Trial design

51 participants in 2 patient groups

Early-onset Alzheimer's disease

Description:

Patients were recruited from the outpatient memory clinics of the Department of Neurology, Dokuz Eylül University Hospital. The patient group was diagnosed by an expert neurologist, according to the National Institute on Aging-Alzheimer's Association diagnostic criteria for Alzheimer's disease

Treatment:

Diagnostic Test: CSF

Healthy controls

Description:

Age-and gender-matched healthy volunteers were recruited via advertisements and word-of-mouth.